Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
August 02, 2017 11:00 ET
|
Verona Pharma plc
LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference
August 01, 2017 07:00 ET
|
Verona Pharma plc
LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
July 26, 2017 02:00 ET
|
Verona Pharma plc
LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
June 27, 2017 02:00 ET
|
Verona Pharma plc
LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
June 22, 2017 07:00 ET
|
Verona Pharma plc
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA
June 05, 2017 08:30 ET
|
Verona Pharma plc
LONDON, June 05, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference
May 23, 2017 08:30 ET
|
Verona Pharma plc
LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising...
Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option
May 18, 2017 14:09 ET
|
Verona Pharma plc
LONDON, May 18, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative...
Grant of Options and RSUs and PDMR Dealings
May 03, 2017 10:08 ET
|
Verona Pharma plc
LONDON, May 03, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative...
Verona Pharma Announces Closing of Global Offering
May 02, 2017 13:53 ET
|
Verona Pharma plc
LONDON, May 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative...